These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31128760)

  • 1. Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay.
    Thongkum W; Hadpech S; Tawon Y; Cressey TR; Tayapiwatana C
    Anal Chim Acta; 2019 Sep; 1071():86-97. PubMed ID: 31128760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expedient screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay.
    Kitidee K; Khamaikawin W; Thongkum W; Tawon Y; Cressey TR; Jevprasesphant R; Kasinrerk W; Tayapiwatana C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():153-158. PubMed ID: 26490422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.
    Kou H; Ye M; Fu Q; Han Y; Du X; Xie J; Zhu Z; Li T
    Sci China Life Sci; 2012 Apr; 55(4):321-7. PubMed ID: 22566088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.
    Hirano A; Takahashi M; Kinoshita E; Shibata M; Nomura T; Yokomaku Y; Hamaguchi M; Sugiura W
    Biol Pharm Bull; 2010; 33(8):1426-9. PubMed ID: 20686242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
    Calcagno A; Pagani N; Ariaudo A; Arduino G; Carcieri C; D'Avolio A; Marinaro L; Tettoni MC; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2017 Jun; 72(6):1741-1744. PubMed ID: 28333285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS.
    Das Mishra T; Kurani H; Singhal P; Shrivastav PS
    J Chromatogr Sci; 2012 Aug; 50(7):625-35. PubMed ID: 22562821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
    Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
    Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.
    Azoulay S; Nevers MC; Créminon C; Heripret L; Garraffo R; Durant J; Dellamonica P; Grassi J; Guedj R; Duval D
    J Immunol Methods; 2004 Dec; 295(1-2):37-48. PubMed ID: 15627609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
    Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
    Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir protein binding in vivo through the 12-hour dosing interval.
    Boffito M; Hoggard PG; Lindup WE; Bonora S; Sinicco A; Khoo SH; Di Perri G; Back DJ
    Ther Drug Monit; 2004 Feb; 26(1):35-9. PubMed ID: 14749547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.
    Estrela RC; Ribeiro FS; Seixas BV; Suarez-Kurtz G
    Rapid Commun Mass Spectrom; 2008; 22(5):657-64. PubMed ID: 18257112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.